Treatment of immune evasive tumors

A method for treating a subject having an immune evasive cancer and who had previously received immunotherapy or in which the cancer is refractory to immunotherapy, comprising administering to the subject negatively charged particles alone or in combination with a cancer therapeutic, wherein the negatively charged particles comprise:

• a polyglycolic acid (PGA) polymer, polylactic acid (PLA), poly (lactic-co-glycolic acid) (PLGA), polystyrene, chitosan, polysaccharide, one or more lipids, diamond, iron, zinc, cadmium, gold, silver, or any combination thereof, wherein the particles have a zeta potential between −30 to −100 mV and a size greater than 200 nm and are free from one or more therapeutic agent,
• wherein the cancer therapeutic is selected from the group consisting of a growth inhibitor, DNA-replication inhibitor, kinase inhibitor, receptor tyrosine kinase inhibitor, signaling cascade inhibitor, angiogenesis inhibitor, metabolic inhibitor, amino acid synthesis inhibitor, selective inhibitor of oncogenic protein, inhibitor of metastasis, inhibitor of anti-apoptosis factor, apoptosis inducer, enzyme inhibitor, nucleoside stimulating inhibitor, antibody-drug conjugate, DNA-damaging agent, cytokines, one or more cell-based therapies, a hormone therapy, one or more cancer vaccines, or one or more immunotherapies selected from the group consisting of:
• oncolytic virus, oncolytic bacteria or other bacterial compositions, Bacillus Calmette-Guerin (BCG), microbiome modulator, Stimulator of interferon genes (STING) pathway modulator, and toll-like receptor (TLR) modulator.